Literature DB >> 23224781

Cancer-related microRNAs and their role as tumor suppressors and oncogenes in hepatocellular carcinoma.

Luc Gailhouste1, Takahiro Ochiya.   

Abstract

MicroRNAs (miRNAs) have emerged as key factors involved in several biological processes, including development, differentiation, cell proliferation, and tumorigenesis. In hepatocellular carcinoma (HCC), miRNAs frequently present aberrant expression profiles, which make them potentially attractive for diagnostic or prognostic applications. Currently, accumulating evidence is indicating the role of miRNAs as tumor suppressors or oncogenes in hepatic malignancies. In particular, comprehensive studies have made possible a better understanding of HCC behavior, such as tumor growth, response to therapies, metastatic potential, or recurrence, regarding the altered expression of cancer-related miRNAs. Based on these findings, efforts are under way to define new markers for liver cancer in both invasive (hepatic biopsy or tumor resection) and non-invasive (circulating miRNAs in blood serum) ways. Due to their implication in the control of various cell processes altered in HCC, cancer-related miRNAs also offer encouraging perspectives for the development of innovative cancer therapies. In this article, we review the importance of miRNA deregulation in HCC progression and the role of these small non-coding RNAs as tumor suppressors and oncogenes. The significance of miRNAs in HCC diagnosis and miRNA-based therapeutic strategies is then discussed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23224781     DOI: 10.14670/HH-28.437

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  29 in total

1.  Androgen receptor in hepatocarcinogenesis: Recent developments and perspectives.

Authors:  Y E Tian; X U Xie; Yao Lin; Guang Tan; W U Zhong
Journal:  Oncol Lett       Date:  2015-03-10       Impact factor: 2.967

2.  MiR-570 inhibited the cell proliferation and invasion through directly targeting B7-H1 in hepatocellular carcinoma.

Authors:  Wei Guo; Wei Tan; Shan Liu; Xuhui Huang; Juze Lin; Ronghua Liang; Le Su; Qiao Su; Changjun Wang
Journal:  Tumour Biol       Date:  2015-06-18

Review 3.  Role of innate immunity in the development of hepatocellular carcinoma.

Authors:  Rajagopal N Aravalli
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

4.  IGF-I receptor as an emerging potential molecular-targeted for hepatocellular carcinoma in vitro and in vivo.

Authors:  Min Yao; Li Wang; Junling Yang; Xiaodi Yan; Yin Cai; Dengfu Yao
Journal:  Tumour Biol       Date:  2016-09-13

5.  MicroRNA-299-3p promotes the sensibility of lung cancer to doxorubicin through directly targeting ABCE1.

Authors:  Dawei Zheng; Yan Dai; Song Wang; Xiaoyu Xing
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 6.  Novel hepatocellular carcinoma molecules with prognostic and therapeutic potentials.

Authors:  Bruna Scaggiante; Maryam Kazemi; Gabriele Pozzato; Barbara Dapas; Rosella Farra; Mario Grassi; Fabrizio Zanconati; Gabriele Grassi
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

Review 7.  MicroRNAome genome: a treasure for cancer diagnosis and therapy.

Authors:  Ioana Berindan-Neagoe; Paloma del C Monroig; Barbara Pasculli; George A Calin
Journal:  CA Cancer J Clin       Date:  2014-08-07       Impact factor: 508.702

Review 8.  MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches.

Authors:  E Callegari; L Gramantieri; M Domenicali; L D'Abundo; S Sabbioni; M Negrini
Journal:  Cell Death Differ       Date:  2014-09-05       Impact factor: 15.828

Review 9.  Role of long non-coding RNA in tumor drug resistance.

Authors:  Heng Deng; Jun Zhang; JinJun Shi; ZhengDong Guo; ChunRong He; Li Ding; Jin Hai Tang; Yong Hou
Journal:  Tumour Biol       Date:  2016-07-05

Review 10.  Molecular events in the pathogenesis of vulvar squamous cell carcinoma.

Authors:  Deyin Xing; Oluwole Fadare
Journal:  Semin Diagn Pathol       Date:  2020-09-25       Impact factor: 3.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.